“There’s also a problem that the ‘normal’ ranges for one
laboratory may be decidedly different than they are for another
laboratory,” says Ronald Swerdloff, chief endocrinologist at Harbor
UCLA Medical Center in California and LA Biomed Inv.
Testosterone supplements promise men a butch boost of resurrected
libido, energy and mood. But there’s a better way to restore
“REDUCED sex drive? Decreased energy? Unwanted mood or body changes?
Is it low testosterone?”
Kythera Biopharmaceuticals’ new drug application (NDA) for its ATX-101, a submental contouring injectable drug, has been accepted for filing by the US Food and Drug Administration (FDA).
According to Kythera Biopharmaceuticals, the ATX-101 NDA will be subject to a standard review and will have a prescription drug user fee act (PDUFA) action date of 13 May 2015. The company submitted the NDA in May 2014.
The FDA’s Division of Dermatology and Dental Products is also planning to hold an Advisory Committee meeting on the company’s ATX-101 application during the review.
Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don’t have easy access to the care they need to manage their diabetes.
Their inability to effectively manage their diabetes puts them at significantly higher risk for long-term complications, including kidney failure, amputations and blindness.
Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company focused on the development and commercialization of REXTORO ( (Testosterone Undecanoate), an oral testosterone (T) replacement product, today presented Phase 3 clinical data from two studies that support the safety and efficacy of REXTORO for T-replacement therapy in men with hypogonadism. These results are being presented from 1-3 p.m.
Biocom, the association for the Southern California life science community, and the San Diego International Airport Art Program announce the return of the cell culture exhibit, a showcase of art from microscopic research contributing to life-changing breakthroughs taking place in the Southern California region.
NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline.
The Palos Verdes Peninsula Coordinating Council presented the Los Angeles Biomedical Research Institute (LA BioMed) with its Community Service Award on May 22, an annual honor it gives to an organization with programs that “greatly benefit the community.”
The Council, formed in 1956, provides programs of interest to the community and publishes an updated calendar of nonprofit events as a service the community. It has been presenting the Community Service Award to local organizations since 1961.
The rates of community-onset methicillin-resistant Staphylococcus aureus (CO-MRSA) varied dramatically among academic medical centers in California, New York, Illinois and North Carolina, suggesting there is not a uniform change in the “national epidemic” of the “superbug” that has generated extensive public health concern over the past decade, according to a new study.
Green tea and its extracts have been widely touted as potential treatments for cancer, as well as several other diseases. But scientists have struggled to explain how the green tea and its extracts may work to reduce the risk of cancer or to slow the growth of cancer cells.
With the rate of chronic kidney disease on the rise among older Americans, researchers seeking to improve patients’ quality of life studied a group of adults undergoing hemodialysis and found their higher rates of depression and anxiety could be associated with their impaired physical exercise capability and reduced daily physical activity, according a new study published online by the Journal of Renal Nutrition.